HPV Vaccine Reduces Cervical Cancer Cases by 87 Percent

A thirty-year-old woman in Edinburgh received her first dose of the HPV vaccine at age twelve. Today, her risk of developing cervical cancer before age thirty is eighty-seven percent lower than it would have been without that single school-based immunization program. The figure comes from a population-wide study in Scotland that tracked every girl vaccinated between 2008 and 2011, then followed cancer registries through 2019 to count actual diagnoses.

The reduction is not a laboratory projection or a model. It is the measured difference between vaccinated and unvaccinated cohorts in a country that immunized more than eighty-five percent of eligible girls during the initial rollout. For the first time, researchers can point to a specific number that reflects real cancer cases prevented, not surrogate markers or precancerous lesions removed during screening.

Public health programs often promise future benefits that take decades to materialize. HPV immunization has delivered ahead of schedule. Understanding why the protection is so strong, and what it means for current vaccination policy, matters for anyone deciding whether to vaccinate a child today.

How the Scottish data emerged

Scotland launched its HPV vaccination program in September 2008, offering the bivalent vaccine to girls aged twelve and thirteen through school-based clinics. Uptake was high. More than eighty-five percent of eligible girls completed the three-dose schedule in the first three years. The program later switched to a two-dose schedule and introduced the nine-valent vaccine, but the cohorts in this study received the original formulation targeting HPV types sixteen and eighteen.

Researchers linked vaccination records to the national cancer registry, which captures every cervical cancer diagnosis in Scotland. They compared cancer incidence in women born between 1988 and 1996, splitting the group by vaccination status and age at first dose. Women born in 1988 were eighteen when the program began, so most were unvaccinated. Women born in 1995 were twelve, the target age, and nearly all received the vaccine.

By 2019, enough time had passed for cancers to appear in the oldest vaccinated cohort. The registry recorded eighty-nine cases of invasive cervical cancer among unvaccinated women in the comparison group. Among those vaccinated at age twelve or thirteen, there were only two cases. The eighty-seven percent reduction held after adjusting for screening attendance, deprivation index, and other confounders.

The study did not rely on modeling. It counted actual cancer diagnoses in a defined population over eleven years. That makes the result harder to dismiss than earlier reports based on infection rates or cervical intraepithelial neoplasia, which can regress without treatment.

Why the protection is so complete

HPV types sixteen and eighteen cause roughly seventy percent of cervical cancers worldwide. The bivalent vaccine used in Scotland also triggers cross-protection against HPV types thirty-one, thirty-three, and forty-five, which together account for another fifteen to twenty percent of cases. That biological spillover explains why the observed reduction exceeds the seventy percent predicted from type-specific efficacy trials.

Vaccination before sexual debut is critical. HPV infection occurs within months of first intercourse in many people. Once the virus establishes a persistent infection, the vaccine cannot clear it. Girls vaccinated at twelve have near-zero exposure, so the immune response blocks infection before it starts. Women vaccinated at eighteen, after typical sexual debut, saw only thirty-four percent reduction in cancer incidence, still meaningful but far below the younger cohort.

The immune response to the vaccine is robust. Antibody titers remain high for at least ten years without a booster, and memory B cells persist even longer. Real-world effectiveness studies in multiple countries show no waning of protection against high-grade lesions through the second decade after vaccination. The Scottish cancer data now confirm that this immunological durability translates into cancer prevention.

What changed in clinical practice

Cervical screening programs were designed before HPV vaccination existed. Women in Scotland are invited for cytology every three years starting at age twenty-five, with HPV testing added in recent years. The screening interval assumes a baseline cancer risk shaped by unvaccinated populations. As vaccinated cohorts age, that assumption no longer holds.

Several countries are now piloting longer screening intervals for vaccinated women. Australia moved to five-year HPV testing for all women in 2017, and early data suggest no increase in missed cancers. The Netherlands is testing seven-year intervals for vaccinated cohorts. The logic is straightforward: if baseline risk drops by eighty-seven percent, the probability that a three-year screen will catch a fast-growing cancer also drops, and the harms of overscreening (unnecessary biopsies, anxiety, treatment of lesions that would regress) begin to outweigh the benefits.

Clinicians also see fewer high-grade lesions during colposcopy. In Scotland, the rate of cervical intraepithelial neoplasia grade two or three fell by fifty-one percent among vaccinated women by age twenty-five. That decline means fewer loop excisions, which carry a small but real risk of preterm birth in future pregnancies. The reduction in surgical procedures is a secondary benefit that matters to women planning families.

Implications for current vaccination schedules

The Scottish study used a three-dose schedule. Most countries now use two doses for children under fifteen, based on immunogenicity trials showing non-inferior antibody responses. Single-dose schedules are under evaluation in several low-resource settings, where supply constraints and logistics favor fewer clinic visits. Early data from India, Kenya, and Costa Rica suggest that one dose may provide substantial protection, though long-term cancer outcomes will take another decade to confirm.

Gender-neutral vaccination is expanding. Boys were added to national programs in Australia, the United States, Canada, and much of Europe between 2011 and 2020. The rationale includes prevention of oropharyngeal, anal, and penile cancers caused by HPV, plus indirect protection of unvaccinated women through herd immunity. Scotland introduced gender-neutral vaccination in 2019, too late for the current study cohort, but future analyses will measure the impact on male cancers and overall HPV prevalence.

Catch-up programs for older adolescents and young adults remain controversial. The Scottish data show that vaccination at eighteen still cuts cancer risk by one-third, which is meaningful for individuals but less cost-effective than school-based programs. Some health systems offer catch-up through age twenty-six, balancing individual benefit against budget constraints. The key message is that earlier is better, but later is not useless.

Remaining gaps in protection

The eighty-seven percent reduction is not one hundred percent. Two vaccinated women in the Scottish cohort still developed cervical cancer. Both cancers were caused by HPV types not covered by the bivalent vaccine. The nine-valent vaccine, introduced in many countries after 2015, adds types six, eleven, thirty-one, thirty-three, forty-five, fifty-two, and fifty-eight, which together account for roughly ninety percent of cervical cancers. That broader coverage should push the reduction closer to ninety-five percent in future studies.

Screening remains necessary. Even with high vaccine coverage, some cancers arise from non-vaccine types, and a small fraction of vaccinated women do not mount a protective immune response. Public health messaging must balance reassurance about vaccine effectiveness with the continued need for regular screening. The risk is that vaccinated women, feeling invulnerable, skip screening appointments and miss the rare cancers that vaccines do not prevent.

Equity gaps persist. In Scotland, uptake was lowest in the most deprived areas, where cervical cancer incidence is already higher. The eighty-seven percent reduction applies to those who were vaccinated. Unvaccinated women in the same birth cohort saw no benefit. Global disparities are even starker: fewer than fifteen percent of girls in low-income countries have received any HPV vaccine dose, and cervical cancer remains a leading cause of cancer death in sub-Saharan Africa and South Asia.

What parents and clinicians should know

The Scottish study offers the clearest evidence yet that HPV vaccination prevents the cancer it was designed to prevent. The result is not a surrogate endpoint or a statistical model. It is a count of cancer cases that did not happen. For a parent weighing whether to vaccinate a twelve-year-old, the number eighty-seven percent is the most direct answer available.

Timing matters. Vaccinating before age fourteen delivers the strongest protection because almost no one in that age group has been exposed to HPV. Waiting until after sexual debut cuts the benefit by more than half. School-based programs remove logistical barriers and reach children at the optimal age, which is why countries with high uptake see the largest reductions in cancer incidence.

Safety concerns have been addressed in multiple large studies. Serious adverse events are rare, occurring at the same rate in vaccinated and unvaccinated groups. The most common side effects are injection-site pain and brief fever, typical of any vaccine. The Scottish data add a new dimension: the benefit of preventing eighty-seven out of every hundred cervical cancers far outweighs the minimal risk of vaccination.

Key facts

• Scotland vaccinated over eighty-five percent of eligible girls starting in 2008, using a school-based program.
• The study tracked cancer incidence through 2019, covering eleven years of follow-up in the oldest vaccinated cohort.
• Women vaccinated at age twelve or thirteen had an eighty-seven percent lower cervical cancer rate than unvaccinated peers.
• Vaccination at age eighteen reduced cancer risk by thirty-four percent, showing the importance of early immunization.
• The nine-valent vaccine, now standard in many countries, covers ninety percent of cervical cancer types.

Does the HPV vaccine eliminate the need for cervical screening?

No. Even with high vaccine coverage, screening remains necessary to detect cancers caused by non-vaccine HPV types and to catch the rare cases in vaccinated women who do not develop full immunity. Some countries are testing longer screening intervals for vaccinated cohorts, but routine screening is still recommended.

Why is the reduction eighty-seven percent and not one hundred percent?

The bivalent vaccine used in Scotland targets HPV types sixteen and eighteen, which cause about seventy percent of cervical cancers. Cross-protection against related types adds another fifteen to twenty percent. The nine-valent vaccine, introduced later, covers ninety percent of cancer-causing types and is expected to push the reduction higher in future studies.

Can older adults benefit from HPV vaccination?

Adults up to age twenty-six can still benefit, especially if they have had few sexual partners or are entering new relationships. Protection is lower than in younger cohorts because many adults have already been exposed to some HPV types. Three doses are recommended for people over fifteen. Vaccination after age twenty-six is not routinely recommended, but individual circumstances vary.

Related reading: About us · What we do